Company news
Spero Therapeutics, Inc. news in 2022
Spero Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Spero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business Update
November 13, 2022
Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr
November 7, 2022
Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
November 6, 2022
Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer
September 14, 2022
Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration
September 5, 2022
Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update
August 9, 2022
Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
August 8, 2022
Spero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application
June 26, 2022
Spero Therapeutics Announces First Quarter 2022 Operating Results and Provides Business Update
May 15, 2022
Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline
May 2, 2022
Spero Therapeutics Announces Fourth Quarter and Full Year 2021 Operating Results and Provides Business Update
March 30, 2022
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 31, 2022
March 16, 2022
Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206, A Novel Intravenous Next Generation Polymyxin Antibiotic for the Treatment of Multi-drug Resistant Gram-Negative Infections in the Hosp...
February 15, 2022
Spero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients
January 18, 2022
Spero Therapeutics Announces Lifting of FDA Clinical Trial Hold on SPR720
January 3, 2022
Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis
January 2, 2022
Calls in 2022
- Spero Therapeutics (NASDAQ:SPRO) Q3 2022 Earnings Call
Nov 14, 2022
Transcript - Spero Therapeutics (NASDAQ:SPRO) Q2 2022 Earnings Call
Aug 10, 2022
Transcript - Spero Therapeutics (NASDAQ:SPRO) Q1 2022 Earnings Call
May 16, 2022
Transcript - Spero Therapeutics (NASDAQ:SPRO) Q4 2021 Earnings Call
Mar 31, 2022
Transcript
Decks in 2022
- Investor Presentation (January 2022)
Investor deck · 36 slides · Jan 25, 2022